The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial

被引：0

作者：

Walensky, R. P. ^{[1
,2
,6
]}

Ross, E. L. ^{[1
]}

Kumarasamy, N. ^{[7
]}

Wood, R. ^{[8
,9
]}

Noubary, F. ^{[1
]}

Paltiel, A. D. ^{[10
]}

Nakamura, Y. M. ^{[1
]}

Godbole, S. ^{[11
]}

Hosseinipour, M. ^{[12
,13
]}

Hakim, J. G. ^{[14
]}

Kumwenda, J. ^{[15
]}

Makhema, J. ^{[5
]}

Akelo, V. ^{[16
]}

Panchia, R. ^{[17
]}

Sanne, I. ^{[18
]}

Weinstein, M. C. ^{[4
]}

Losina, E. ^{[3
,6
,19
]}

Mayer, K. H. ^{[20
]}

Grinsztejn, B. ^{[21
]}

Pilotto, J. ^{[22
,23
]}

Chariyalertsak, S. ^{[24
]}

Santos, B. ^{[25
]}

Chen, Y. Q. ^{[26
]}

Wang, L. ^{[26
]}

Li, X. ^{[26
]}

McCauley, M. ^{[27
]}

Gamble, T. ^{[28
]}

Piwowar-Manning, E. ^{[29
]}

Cottle, L. ^{[30
]}

Hoffman, I. ^{[31
]}

Eron, J. ^{[31
]}

Gallant, J. ^{[29
]}

Swindells, S. ^{[32
]}

Taha, T. ^{[33
]}

Nielsen-Saines, K. ^{[34
]}

Celentano, D. ^{[33
]}

Essex, M. ^{[4
]}

Elharrar, V. ^{[35
]}

Burns, D. ^{[35
]}

Seage, G. R. ^{[4
]}

Cohen, M. S. ^{[31
]}

Freedberg, K. A. ^{[1
,2
,19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Harvard Ctr AIDS Res, Boston, MA USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Botswana Harvard AIDS Inst, Gaborone, Botswana

[6] Brigham & Womens Hosp, Boston, MA 02115 USA

[7] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India

[8] Univ Cape Town, ZA-7925 Cape Town, South Africa

[9] Desmond Tutu HIV Ctr, Cape Town, South Africa

[10] Yale Univ, Sch Med, New Haven, CT USA

[11] NARI, Pune, Maharashtra, India

[12] Univ N Carolina Chapel Hill, Lilongwe, Malawi

[13] UNC Project Malawi, Lilongwe, Malawi

[14] Univ Zimbabwe, Dept Med, Harare, Zimbabwe

[15] Coll Med Johns Hopkins Project, Blantyre, Malawi

[16] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya

[17] Univ Witwatersrand, PHRU, Johannesburg, South Africa

[18] Univ Witwatersrand, Dept Med, Johannesburg, South Africa

[19] Boston Univ, Sch Publ Hlth, Boston, MA USA

[20] Fenway Inst, Boston, MA USA

[21] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil

[22] Fiocruz MS, Hosp Geral Nova Iguacu, BR-21045900 Rio De Janeiro, Brazil

[23] Fiocruz MS, Lab AIDS & Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil

[24] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand

[25] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil

[26] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA

[27] FHI 360, Washington, DC USA

[28] FHI 360, Durham, NC USA

[29] Johns Hopkins Sch Med, Baltimore, MD USA

[30] SCHARP, Seattle, WA USA

[31] Univ N Carolina, Sch Med, Chapel Hill, NC USA

[32] Univ Nebraska Med Ctr, Omaha, NE USA

[33] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA

[34] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA

[35] NIAID, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：116 / 117

页数：2

共 50 条

[41] COST-EFFECTIVENESS ANALYSIS OF HEPATITIS-A PREVENTION IN TRAVELERS
TORMANS, G
VANDAMME, P
VANDOORSLAER, E
VACCINE, 1992, 10 : S88 - S92
[42] Methadone maintenance and HIV prevention: A cost-effectiveness analysis
Zaric, GS
Brandeau, ML
Barnett, PG
MANAGEMENT SCIENCE, 2000, 46 (08) : 1013 - 1031
[43] Virologic outcomes in early antiretroviral treatment: HPTN 052
Eshleman, Susan H.
Wilson, Ethan A.
Zhang, Xinyi C.
Ou, San-San
Piwowar-Manning, Estelle
Eron, Joseph J.
McCauley, Marybeth
Gamble, Theresa
Gallant, Joel E.
Hosseinipour, Mina C.
Kumarasamy, Nagalingeswaran
Hakim, James G.
Kalonga, Ben
Pilotto, Jose H.
Grinsztejn, Beatriz
Godbole, Sheela V.
Chotirosniramit, Nuntisa
Santos, Breno Riegel
Shava, Emily
Mills, Lisa A.
Panchia, Ravindre
Mwelase, Noluthando
Mayer, Kenneth H.
Chen, Ying Q.
Cohen, Myron S.
Fogel, Jessica M.
HIV CLINICAL TRIALS, 2017, 18 (03): : 100 - 109
[44] The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study
Adamson, Blythe
El-Sadr, Wafaa
Dimitrov, Dobromir
Gamble, Theresa
Beauchamp, Geetha
Carlson, Josh J.
Garrison, Louis, Jr.
Donnell, Deborah
VALUE IN HEALTH, 2019, 22 (02) : 194 - 202
[45] Cost-effectiveness of Fosamax® (alendronate) for the treatment of osteoporosis and prevention of fractures
Johnell, O
Jönsson, B
Jönsson, L
Black, D
OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S9 - S9
[46] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
HIMMELSTEIN, DU
WOOLHANDLER, S
BOR, DH
CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
[47] How HIV treatment advances affect the cost-effectiveness of prevention
Pinkerton, SD
Holtgrave, DR
MEDICAL DECISION MAKING, 2000, 20 (01) : 89 - 94
[48] Cost-effectiveness of Fosavance® in the treatment and prevention of osteoporosis in the United Kingdom
Jansen, J.
Gaugris, S.
Bergman, G.
Sen, S. S.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S96 - S96
[49] Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
Aigbogun, Myrlene S.
Liu, Sizhu
Kamat, Siddhesh A.
Sapin, Christophe
Duhig, Amy M.
Citrome, Leslie
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 443 - 456
[50] Screening, prevention, and treatment of cervical cancer - A global and regional generalized cost-effectiveness analysis
Ginsberg, G. M.
Tan-Torres, Edeger T.
Lauer, J. A.
Sepulveda, C.
VALUE IN HEALTH, 2008, 11 (03) : A62 - A62

← 1 2 3 4 5 →